Ziccum is reorganizing its administrative functions, due to the increased amount of business dialogues and to perform financial reporting in a more streamlined fashion. Two new roles of Business & Project Manager and a business-oriented, junior Financial Manager are introduced while the CFO role is eliminated.

As Ziccum is progressing generating strong data for LaminarPaceTM treatment of mRNA/LNP modalities, the industry interest is growing and business dialogues are increasing in number, requiring more resources to be well taken care of. The successful licensing business model, based on technology licensing and including paid feasibility programs, has been rewarded by agreements with leading Pharma and Biotech partners requiring project execution in addition to the internal development projects. The company is therefore recruiting for a position as Business & Project Manager, where final candidates with excellent credentials have been selected.

In parallel, a more efficient solution to perform company public reporting has been established by setting up limited consultant support from the Ziccum accounting partner, Ekonomistubben. The new organizational set-up is also complemented by the hiring of a junior Finance Manager with business profile, who will have an active role in partner interaction as well as investor relations and soft funding. Ziccum has recruited a young US-educated talent with advisory background in New York plus London, Christo Vassilev.

As a consequence of the reorganization the position as Chief Financial Officer is eliminated and the current person holding this position, Johny Humaloja, has been given notice to leave Ziccum. He will maintain his role for a smooth and efficient handover, to ensure good adherence to the Nasdaq First North requirements.

Ziccum CEO Ann Gidner: “This carefully planned re-organization is strengthening the Ziccum team and will contribute to the successful continued development of the company and its business, better harnessing the significant industry interest, while keeping spending at an optimal level for Ziccum’s current development stage. We have succeeded very rapidly building our reputation in international industry and we are delighted to strengthen our team accordingly with talented candidates, giving Christo a very warm welcome. We are thanking Johny for the efforts spent at Ziccum.”

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75
 
Ziccum’s Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on https://eucaps.com/ziccum

About Ziccum

Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum strengthens and streamlines business and finance functions

© Modular Finance, source Nordic Press Releases